National Advertising Division Finds Lumineux Whitening Strips “Sensitivity” Claim Supported; Recommends Other Claims be Discontinued or Modified

New York, NY – November 6, 2023 – In a challenge brought by the Procter & Gamble Company (P&G), the National Advertising Division (NAD) of BBB National Programs determined that Oral Essentials, Inc. (OEI) provided a reasonable basis for its on-pack claim that Lumineux Whitening Strips “whitens without the sensitivity.”

However, NAD recommended that OEI discontinue the claim “30 minutes to whiter teeth” or modify it to avoid conveying the message that consumers will experience whiter teeth after using the Lumineux product once for 30 minutes. 

 

“Whitens Without the Sensitivity”

In support of its “whitens without the sensitivity” claim, OEI relied on two clinical studies, which NAD determined provided reasonable support for the challenged claim. Further, NAD concluded that P&G’s clinical study did not offer more reliable evidence than the studies provided by OEI with respect to whitening-related sensitivity.

 

“30 Minutes to Whiter Teeth”

NAD found that consumers may reasonably understand the claim “30 minutes to whiter teeth” to mean they will experience noticeably whiter teeth after using the Lumineux Whitening Strips after a single 30-minute application even though the details on the packaging reference that the full whitening effect takes 14 treatments.   

Further, NAD determined that OEI’s proposed disclosure of “when used daily for at least 7 days as directed” would not prevent a misleading message because it would contradict the main message of the claim.

For these reasons, NAD recommended that OEI discontinue the claim “30 minutes to whiter teeth” or modify it to avoid conveying the message that consumers will experience whiter teeth after using the Lumineux product once for 30 minutes. 

In its advertiser statement, OEI stated that it “appreciates NAD finding the claim that Lumineux Whitening Strips ‘whiten without the sensitivity’ to be supported by clinical studies. As a strong supporter of the self-regulatory process, OEI will follow NAD’s recommendations and modify claims regarding the duration of usage of Lumineux Whitening Strips needed to achieve whitening.”  

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB procedures, this release shall not be used for advertising or promotional purposes.

 

Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.

 

 

 

 

Latest Decisions

Decision

National Advertising Division Recommends Dr. Luke Healthcare Discontinue Treatment Claims for its Fungal Nail Renewal Product

New York, NY – July 24, 2024 – The National Advertising Division recommended Dr. Luke Healthcare discontinue certain claims for Dr. Luke’s Fungal Nail Renewal product, including health-related claims, natural claims, and claims that a doctor recommends the product or that it treats a medical condition.

Read the Decision Summary
Decision

National Advertising Division Finds Flag Image on Kendamil Infant Formula Packaging Conveys Supported Message about Products’ Origin

New York, NY – July 17, 2024 – In a Fast-Track SWIFT challenge, the National Advertising Division determined that use of a flag image on product packaging for Kendal Nutricare’s Kendamil infant formula reasonably conveys a supported message about the products’ origin. 

Read the Decision Summary
Decision

In National Advertising Division Case, GuruNanda Voluntarily Discontinues Claims Made through Influencers for Coconut Pulling Oil Products

New York, NY – July 16, 2024 – The National Advertising Division has closed a Fast-Track SWIFT challenge regarding claims that GuruNanda’s coconut pulling oil products can “naturally reverse a cavity” and “reverse cavities.” 

Read the Decision Summary
Decision

National Advertising Division Refers Health-Related Advertising Claims for Prolacta’s Human Milk Fortifier to Regulatory Agencies

New York, NY – July 15, 2024 – The National Advertising Division will refer advertising claims made by Prolacta Bioscience for its Human Milk Fortifier to the Federal Trade Commission (FTC) and Food and Drug Administration (FDA) for review.

Read the Decision Summary